OUR PRODUCTS
FORMULATION

Each film-coated tablet contains Ciprofloxacin (as Hydrochloride), 500mg.

DOSAGE AND ADMINISTRATION

The dosage of Ciprofloxacin tablets is determined on the basis of severity of infection, type of infecting organism and age, weight, and renal function of the patient. The recommended dosage is as follows: Uncomplicated UTI: 250mg every 12 hours. Prostatitis and Complicated UTI in patients with severe underlying structural abnormalities: 500 mg every 12 hours. Lower respiratory tract infection: Mild: 250mg; Moderate to severe: 500mg every 12 hours. Dosage of 750mg every 12 hours should preferably be used in cases of infection with resistant Gram-positive bacteria. Gynecological infections: 500mg every 12 hours. The dosage should be adjusted in patients with renal impairment. Or as prescribed by the physician.

INDICATION

For treatment of wide variety of infections caused by Gram-positive and Gram-negative organisms.

CONTRAINDICATION

Hypersensitivity to Ciprofloxacin and other quinolone derivative. Pregnancy and lactation. Children below 12 years of age.

SPECIAL PRECAUTIONS

To be used with caution in patients with CNS disorders. Dosage to be reduced in patients with impaired kidney function. Concurrent administration of antacids to be avoided. Patients receiving Ciprofloxacin should be well-hydrated to prevent crystalluria.

ADVERSE EFFECTS

Ciprofloxacin is generally well tolerated. The commonly reported side effects are diarrhea, vomiting, abdominal pain, headache, restlessness and rash. Other side effects reported very rarely are arthralgia and increase in serum transaminase level.

DRUG INTERACTIONS

Ciprofloxacin absorption is decreased when co-administered with magnesium-aluminum antacids. Other actions, such as calcium, iron and probably zinc appear to interact in a similar manner. Theophylline serum concentrations have been found to be markedly elevated when co-administered with Ciprofloxacin. At doses used for systemic infections, Ciprofloxacin decreases theophylline clearance by approximately 30%. A decreased Ciprofloxacin absorption have been observed with concurrent Sucralfate administration. It is possible that Rifampicin may induce the metabolism of Ciprofloxacin leading to lower serum concentration and failure therapy. The combination of Ciprofloxacin and Chloramphenicol may be antagonistic.

GERMANY
KOHLENSERSLAUTERN
67663 KAISERSLAUTERN
GERMANY

ASIA PACIFIC - PHILIPPINES
2204-C West Tektite Tower, Philippine Stock Exchange Center Exchange Rd.,
Ortigas Center, Pasig City,
Philippines

EMAIL
eisaac@verheilenpharma.com
info@verheilen.com
info@verheilenpharma.com

Verheilen Pharmaceuticals Inc. © 2015 All rights reserved.

Translate »